Williamson Susan Ann 4

What Happened

• Susan A. Williamson, EVP & Chief Compliance Officer of Keenova Therapeutics plc, received a grant of 15,936 restricted stock units (RSUs) on Feb 25, 2026. The Form 4 records the award as a derivative acquisition at $0.00 (no cash was paid).
• Each RSU will settle into one ordinary share upon vesting; the units vest ratably on each of the first three anniversaries of Feb 25, 2027. The grant reflects an adjustment of 1,973 additional RSUs related to the November 10, 2025 separation of Par Health, Inc.

Key Details

• Transaction date: 2026-02-25; Filing date: 2026-02-26 (timely, next-day filing).
• Security/amount: 15,936 RSUs (derivative award); reported price $0.00.
• Vesting/settlement: RSUs convert 1-for-1 to ordinary shares; vest ratably on Feb 25 of 2027, 2028, and 2029.
• Footnotes: F1 (1:1 settlement), F2 (three-year ratable vesting starting 2/25/2027), F3 (1,973 RSUs added due to Par Health separation).
• Shares owned after transaction: not specified in this Form 4.

Context

• This transaction is an equity compensation award (code A) rather than a market purchase or sale. RSU grants are common for employee compensation and do not by themselves signal immediate buying or selling sentiment—value is realized only if and when units vest and convert to shares.
• Because the grant was recorded at $0, the economic value to Ms. Williamson depends on Keenova’s share price at settlement/vesting dates.